Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 409-422

  Go, Ronald S ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IPROPLATIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0032947768     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.409     Document Type: Review

References (113)

1. Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699, 1965
2. Rosenberg B, Van Camp L, Grimley EB, et al: The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 242:1347-1352, 1967
3. Pascoe JM, Roberts JJ: Interactions between mammalian cell DNA and inorganic platinum compounds: II. Interstrand cross-linking of isolated and cellular DNA by platinum (IV) compounds. Biochem Pharmacol 23:1345-1357, 1974
4. Pinto AL, Lippard SJ: Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780:167-180, 1985
5. Roberts JJ, Knox RJ, Pera MF, et al: The role of platinum-DNA interactions in the cellular toxicity and anti-tumor effects of platinum coordination compounds, in Nicolini M (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston, MA, Martinus Wighoff, 1988, pp 16-31
6. Zwelling LA, Michaels S, Schwartz H, et al: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 4:640-649, 1981
7. Plooy AC, van Dijk M, Lohman PH: Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 44:2043-2051, 1984
8. Shionoya S, Lu Y, Scanlon KJ: Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Res 46:3445-3448, 1986
9. Guarino AM, Miller DS, Arnold ST, et al: Platinate toxicity: Past, present and prospects. Cancer Treat Rep 63:1475-1483, 1979
10. Vassilev PM, Kanazirska MP, Charamella LJ, et al: Changes in calcium channel activity in membranes from cis-diamminedichloroplatinum(II)-resistant and -sensitive L1210 cells. Cancer Res 47:519-522, 1987
11. Gordon JA, Gattone VH: Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991-F998, 1986
12. Hongo A, Seid S, Akiyama K, et al: A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem 26:1009-1116, 1994
13. de Boer JG, Glickman BW: Mutations recovered in the Chinese hamster aprt gene after exposure to carboplatin: A comparison with cisplatin. Carcinogenesis 13:15-17, 1992
14. Knox RJ, Friedlos F, Lydall DA, et al: Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(Il) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979, 1986
15. Sundquist WI, Lippard SJ, Stollar BD: Monoclonal antibodies to DNA modified with cis- or trans diamminedichloroplatinum (II). Proc Natl Acad Sci USA 84:8225-8229, 1987
16. Eichholtz-Wirth H, Hietel B: The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 54:239-243, 1986
17. Gately DP, Howell SB: Cellular accumulation of anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176, 1993
18. Fujii R, Mutoh M, Niwa K, et al: Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85:426-433, 1994
19. Parker RJ, Eastman A, Bostick-Bruton F, et al: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87:772-777, 1991
20. Ishikawa T, Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125, 1993
21. Eastman A: Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 61:241-248, 1987
22. Gosland M, Lum B, Schimmelpfennig J, et al: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16:16-39, 1996
23. Hishikawa Y, Abe S, Kinugasa S, et al: Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 54:342-347, 1997
24. Siu LL, Banerjee D, Khurana RJ, et al: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559-565, 1998
25. Timmer-Bosscha H, Mulder NH, de Vries EG, et al: Modulation of cis-diamminechloroplatinum(II) resistance: A review. Br J Cancer 66:227-238, 1992
26. Kelland LR: New platinum antitumor complexes. Crit Rev Oncol Hematol 15:191-219, 1993
27. Adjei AA, Budihardjo I, Rowinsky EK, et al: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal. Clin Cancer Res 3:761-770, 1997
28. Bhushan A, Abramson R, Chiu JF, et al: Expression of c-fos m human and murine multidrug-resistant cells. Mol Pharmacol 42:69-74, 1992
29. Isonishi S, Hom DK, Thiebaut FB, et al: Expression of the c-Has-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51:5903-5909, 1991
30. Niimi S, Nakagawa K, Yokota J, et al: Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63:237-241, 1991
31. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
32. Fajac A, Da Silva J, Ahomadegbe JC, et al: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68:67-74, 1996
33. Himmelstein KJ, Patton TF, Belt RJ, et al: Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658-664, 1981
34. Oguri S, Sakakibara T, Mase H, et al: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208-215, 1988
35. Vermorken JB, Van der Vijgh WJF, Klein I, et al: Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68:505-513, 1984
36. Elferink F, Van der Vijgh WJF, Klein I, et al: Pharmacokinetics of diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin) after intravenous administration. Cancer Treat Rep 71:1231-1237, 1987
37. Reed E, Dabholkar M, Chabner BA: Platinum analogues, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 357-378
38. Egorin MJ, Van Echo DA, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)-platinum in patients with impaired renal function. Cancer Res 44:5432-5438, 1984
39. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
40. Schurig JE, Rose WC, Catino JJ, et al: The pharmacologic characteristics of carboplatin: Preclinical experience, in Bunn PA, Canetta R, Ozols RF, et al (eds): Carboplatin (JM-8), Current Perspectives and Future Directions. Philadelphia, PA, WB Saunders, 1990, pp 3-17
41. Rose WC, Schurig JE: Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12:1-19, 1985 (suppl A)
42. O'Hara JA, Douple EB, Richmond RC: Enhancement of radiation induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells. Int J Radiat Oncol Biol Phys 12:1419-1422, 1986
43. Dewit L: Combined treatment of radiation and cis-diamminedichloroplatinum(II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426, 1987
44. Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909, 1981
45. Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in control of cisplatin-induced emesis. N Engl J Med 322:846-848, 1990
46. Morrow GR, Hickok JT, Rosenthal SN: Progress in reducing nausea and emesis: Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 76:343-357, 1995
47. Canetta R, Goodlow J, Smaldone L, et al: Pharmacologic characteristics of carboplatin: Clinical experience, in Bunn PA, Canetta R, Ozols RF, et al (eds): Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA, WB Saunders, 1990, pp 19-38
48. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, et al: Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol 9:308-316, 1986
49. Daugaard G, Abildgaard U: Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1-9, 1989
50. Song SY, Chary KK, Higby DJ, et al: cis-Diamminedichloride platinum(II) in the treatment of metastatic malignant melanoma. Clin Res 25:411A, 1977 (abstr)
51. Ozols RF, Corden BJ, Jacob J, et al: High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19-24, 1984
52. Al-Sarraf M, Fletcher W, Oishi N, et al: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66:31-35, 1982
53. Ostrow S, Egorin MJ, Hahn D, et al: High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73-78, 1981
54. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev 21:33-64, 1995
55. van der Vijgh WJF, Peters GJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): Preclinical aspects. Semin Oncol 21:2-7, 1994 (suppl 2)
56. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
57. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin, and vinblastine in metastatic non-small cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 14:1913-1921, 1996
58. Mason MD, Nicholls J, Horwich A: The effect of carboplatin on renal function in patients with metastatic germ cell tumours. Br J Cancer 23:630-633, 1991
59. Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16:195-211, 1989
60. Poirier MC, Reed E, Litterst CL, et al: Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-153, 1992
61. Gregg RW, Molepo M, Monpetit VJA, et al: Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795-803, 1992
62. Stadnicki SW, Fleischman RW, Schaeppi U, et al: Cischlorodiammine platinum(II) (NSC-119875): Hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 59:467-480, 1975
63. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
64. Hilkens PH, Pronk LC, Verweij J, et al: Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75:417-422, 1997
65. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
66. Alberts DS, Noel JK: Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs 6:369-383, 1995
67. Von Hoff DD, Schilsky R, Reichert CM, et al: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527-1531, 1979
68. Hoskins PJ, O'Reilly SE, Swenerton KD, et al: Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 10:1561-1568, 1992
69. Kato T, Nishimura H, Yamabe T, et al: Phase III study of carboplatin in ovarian cancer. Jpn J Cancer Chem 15:2297-2304, 1988
70. ten Bokkel Huinink WW, Dalesio O, Rodenhuis S, et al: Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: Long term treatment results of a study of the gynaecological cancer cooperative group of the EORTC and experience at the Netherlands Cancer Institute. Semin Oncol 19:99-101, 1992 (suppl 2)
71. Adams M, Kerby IJ, Evans A, et al: A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28:57-60, 1987
72. Mangioni C, Bolis G, Pecorelli S, et al: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464-1471, 1989
73. Edmonson JH, McCormack GM, Wieand HS, et al: Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 81:1500-1504, 1989
74. Gurney H, Crowther D, Anderson H, et al: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol 1:427-433, 1990
75. Conte PF, Bruzzone M, Carnino F, et al: Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: A randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 9:658-663, 1991
76. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992
77. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
78. Belpomme D, Bugat R, Rives M, et al: Carboplatin versus cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III-IV ovarian carcinoma: Results of an ARTAC phase III trial. Proc Am Soc Clin Oncol 11:227, 1992 (abstr 722)
79. Taylor AE, Wiltshaw E, Gore ME, et al: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12:2066-2070, 1994
80. Meerpohl HG, Sauerbrei W, Kuhnle H, et al: Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. Gynecol Oncol 66:75-84, 1997
81. Aabo K, Adnitt P, Adams M, et al: Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 303:884-893, 1991
82. Nejit JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16:352, 1997 (abstr 1259)
83. du Bois A, Nitz U, Schroder W, et al: Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: Interim analysis of an AGO Study Group trial. Proc Am Soc Clin Oncol 16:357, 1997 (abstr 1272)
84. International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
85. Tjulandin SA, Garin AM, Mescheryakov AA, et al: Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 4:663-667, 1993
86. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598-606, 1993
87. Bokemeyer C, Kohrmann O, Tischler J, et al: A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good-risk metastatic non-seminomatous germ cell tumors. Ann Oncol 7:1015-1021, 1996
88. Horwich A, Sleijfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional medical research council/ European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844-1852, 1997
89. Bunn PA: Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol 19:1-11, 1992 (suppl 2)
90. Wolf M, Havemann K, Drings P, et al: Alternating chemotherapy with doxorubicin, ifosfamide, and vincristine plus cisplatin and etoposide versus doxorubicin, ifosfamide, and vincristine plus carboplatin and etoposide in small cell lung cancer, in Bunn PA, Canetta R, Ozols RF, et al (eds): Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA, WB Saunders, 1990, pp 283-294
91. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5:601-607, 1994
92. Lassen U, Kristjansen PEG, Osterlind K, et al: Superiority of cisplatin carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer: A randomized trial with 5 years follow-up. Ann Oncol 7:365-371, 1996
93. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
94. Klatersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562, 1990
95. Bonomi P, Kim K, Kusler J, et al: An ECOG phase III trial: Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small cell lung cancer. Oncology 11:9-10, 1997 (suppl 3)
96. Belani CP, Ramanathan RK: Chemotherapy for advanced non-small cell lung cancer: Past, present, and future. Semin Oncol 24:440-454, 1997
97. Browman GP, Cronin L: Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 21:311-319, 1994
98. De Andres L, Brunet J, Lopez-Pousa A, et al: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13:1493-1500, 1995
99. Welkoborsky HJ, Bleier R, Wissen-Siegert I: Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers: Results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin. Laryngol Rhinol Otol 71:261-266, 1992
100. Ebeling O, Eckel HE, Volling P, et al: Cisplatin/5-FU versus carboplatin/5-FU: 5 year follow-up [in German]. HNO 42:629-635, 1994
101. Scher HI, Shipley WU, Herr HW: Cancer of the bladder, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1300-1318
102. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
103. Bellmunt J, Ribas A, Eres N, et al: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997
104. Petrioli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77:344-351, 1996
105. Omura GA, Blessing JA, Vaccarello L, et al: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 15:165-171, 1997
106. Noda K, Kato T, Ikeda M, et al: Phase II study of carboplatin in cervical carcinoma. Jpn J Cancer Chemother 15:3067-3072, 1988
107. Weiss GR, Green S, Hannigan EV, et al: A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of uterine cervix: A Southwest Oncology Group study. Gynecol Oncol 39:332-336, 1990
108. Lira-Puerto V, Silva A, Morris M, et al: Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol 28:391-396, 1991
109. Thigpen TJ, Blessing J, Holmseley H, et al: Phase III trial of doxorubicin and cisplatin in advanced or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 12:261, 1993 (abstr 830)
110. Long HJ, Pfeifle DM, Wieand HS, et al: Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 80:276-278, 1988
111. Green JB III, Green S, Alberts DS, et al: Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 75:696-700, 1990
112. Burke TW, Munkarah A, Kavanagh JJ, et al: Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51:397-400, 1993
113. Kelsen D, Atiq OT: Therapy of upper gastrointestinal tract cancers. Curr Probl Cancer 15:237-294, 1991